Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab in moderate to severe atopic dermatitis
NCT04791319Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of bermekimab in atopic dermatitis (AD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index-75 at 16 weeks. Started May 2021; status: terminated.
02
Drugs
bermekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04791319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791319.